Weekly Recap | Alumis -50.4%, consensus target above spot
I'm LongbridgeAI, I can summarize articles.Alumis fell 50.4% this week to close at $11.10, while the S&P 500 edged up 0.09%. The stock underperformed the benchmark by roughly 50.49 percentage points. On Monday (31 Aug) it finished at $21.81, then gapped down sharply on Tuesday (1 Sep), touching an intraday low of $8.75 before a partial rebound in the following sessions. The weekly amplitude reached 61.89% on heavy turnover.
The Week
Alumis fell 50.4% this week to close at $11.10, while the S&P 500 edged up 0.09%. The stock underperformed the benchmark by roughly 50.49 percentage points. On Monday (31 Aug) it finished at $21.81, then gapped down sharply on Tuesday (1 Sep), touching an intraday low of $8.75 before a partial rebound in the following sessions. The weekly amplitude reached 61.89% on heavy turnover.
Key Events
The main story was the Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus, which missed its primary endpoint. The company disclosed the result on the evening of 1 Sep, and the stock sold off sharply the next day on unusually heavy volume. Later that day, Alumis noted the drug showed strong efficacy in IFNGS-high patients and was well tolerated, though the overall population missed primary and secondary endpoints. From mid-week, attention shifted to expectations for the psoriasis candidate, helping prices partially recover from the lows. The company also announced it would present at the Wells Fargo annual healthcare investor conference and other September events.
Analyst Ratings
Ten analysts cover Alumis: 8 rate it buy, 1 overweight and 1 hold. The consensus rating is strong buy, with an average target of $32.125, about 189.4% above the current price of $11.10. Targets range from $15 to $46, showing wide dispersion. Ranked against 205 peers in the pharmaceutical industry, Alumis sits at 40th.
The Week Ahead
US macro data picks up next week: NFIB small business optimism on Tuesday, 8 Sep, and initial jobless claims, final demand PPI, core PPI, existing home sales, wholesale sales and EIA natural gas inventories on Thursday, 10 Sep. On the company side, upcoming September investor conferences may provide more colour on the psoriasis programme.
In Short
Alumis had a sharp drawdown after the lupus trial miss, with the price hitting a fresh low of $8.75 before a partial bounce. Heavy one-day volume and a partial recovery contrasted with a consensus target that remains well above spot, highlighting the gap between valuation and near-term sentiment. The key question is whether the psoriasis pipeline offers a clearer path in the coming investor meetings, against a busy macro calendar.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.